Discontinuing Antiseizure Medications After Acute Symptomatic Neonatal Seizures: The Great Trepidation

The developing brain is particularly vulnerable to internal and external stressors, and it is no surprise that clinicians in the field of neonatal neurology fiercely debate the urgency of treating neonatal seizures while at the same token advocate minimizing exposure to potentially toxic antiseizure medications (ASMs). In this issue of Neurology (R) Clinical Practice, Carrasco et al.1 explored the evidence for early discontinuation of ASMs after acute symptomatic seizures in neonates and provide a pragmatic framework for clinicians to use in practice.